STERO Biotechs Ltd.

STERO Ltd., founded in 2017 and headquartered in Israel, is a clinical-stage company committed to the research and development of novel Cannabidiol (CBD) based treatments and solutions that will potentially benefit millions of patients by reducing the side effects and the need of steroid therapy.

STERO’s patent was ISSUED in the US on August 2018.
The patent’s exceptional strength is mainly due to its extremely wide coverage.

Stero has currently three ongoing clinical trials:

  • Phase 2a clinical trials on Steroid Dependent Crohn’s disease (IBD) started on Q1 2020, and on Chronic Urticaria (Hives) started on Q3 2020.
  • Phase 1/2 clinical trial for severe Covid19 patients was completed on Q1 2021 and a phase 2b will commence shortly!

Additional clinical trials are planned during 2021 for more indications in the pipeline.

STERO addresses multiple significant market opportunities. Steroids are the first line of treatment for many inflammatory and autoimmune diseases, including AutoImmune Hepatitis, Rheumatoid Arthritis, Lupus, IBD, COPD, Psoriasis and more.

Stero’s abilities to lower the steroid dosage needed, allowing refractory patients to receive steroid treatments and enhancing the current steroid treatments are all around groundbreaking